Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated in hematopoietic cancers. STAT3 and STAT5 are common targets for different tyrosine kinase oncogenes (TKOs). In addition,...

Full description

Bibliographic Details
Main Authors: Marie Brachet-Botineau, Marion Polomski, Heidi A. Neubauer, Ludovic Juen, Damien Hédou, Marie-Claude Viaud-Massuard, Gildas Prié, Fabrice Gouilleux
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
stat3
stat5
hematopoietic cancers
therapeutic targeting
pharmacological inhibitors
Online Access:https://www.mdpi.com/2072-6694/12/1/240

Internet

https://www.mdpi.com/2072-6694/12/1/240

Similar Items